Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Anil ChandrakerAnil RegmiReginald GohhAkhil SharmaE Steve WoodleMohammed Javeed AnsariVinay NairLing-Xin ChenTarek AlhamadSilas P NormanDiane CibrikManpreet SinghArnold AlperDivya JainZiad ZakyStuart J KnechtleAsif SharfuddinGaurav GuptaBonnie E LonzeJo-Anne H YoungDeborah AdeyArman FaravardehDarshana M DadhaniaAna P RossiDiana FlorescuFrancesca CardarelliJulie MaSarah GilmoreSpyridoula VasileiouPeter JindraDavid WojciechowskiPublished in: Journal of the American Society of Nephrology : JASN (2024)
Posoleucel was generally safe, well tolerated, and associated with a larger reduction of BK viremia compared to placebo. Limitations of this study include the relatively short duration of follow-up and lack of power to detect significant differences in clinical outcomes.